These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6229228)

  • 21. "Lupus" anticoagulant and thrombosis--possible role of inhibition of prostacyclin formation.
    Carreras LO; Vermylen JG
    Thromb Haemost; 1982 Aug; 48(1):38-40. PubMed ID: 6813993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiphospholipid syndrome in systemic lupus erythematosus.
    Hill GS; Nochy D
    J Am Soc Nephrol; 2007 Sep; 18(9):2461-4. PubMed ID: 17699810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombotic cerebral arteriopathy in patients with the antiphospholipid syndrome.
    Hughson MD; McCarty GA; Sholer CM; Brumback RA
    Mod Pathol; 1993 Nov; 6(6):644-53. PubMed ID: 8302806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pulmonary hypertension associated with systemic lupus erythematosus: predominantly thrombotic arteriopathy accompanied by plexiform lesions.
    Yokoi T; Tomita Y; Fukaya M; Ichihara S; Kakudo K; Takahashi Y
    Arch Pathol Lab Med; 1998 May; 122(5):467-70. PubMed ID: 9593350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The characteristics of kidney involvement in a female patient with systemic lupus erythematosus and the antiphospholipid syndrome].
    Kozlovskaia NL; Kabaenkova GS; Varshavskiĭ VA; Shvetsov MIu
    Klin Med (Mosk); 1995; 73(3):93-6. PubMed ID: 8577127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fibrinolysis--a review.
    Kane KK
    Ann Clin Lab Sci; 1984; 14(6):443-9. PubMed ID: 6239587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Defibrination with ancrod in glomerulonephritis: effects on clinical and histologic findings and on blood coagulation.
    Pollak VE; Glueck HI; Weiss MA; Lebron-Berges A; Miller MA
    Am J Nephrol; 1982; 2(4):195-207. PubMed ID: 6816068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Soluble fibrin complex production and proteolysis during ancrod therapy.
    McKillop C; Edgar W; Prentice CR; Forbes CD
    Scott Med J; 1975 May; 20(3):139-40. PubMed ID: 127379
    [No Abstract]   [Full Text] [Related]  

  • 29. The clotting defect in SLE.
    Byron MA
    Clin Rheum Dis; 1982 Apr; 8(1):137-51. PubMed ID: 6811189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative effects of ancrod, urokinase and heparin on intraglomerular coagulation induced by progressive Masugi nephritis (author's transl)].
    Fujioka M
    Nihon Jinzo Gakkai Shi; 1980 Aug; 22(8):1113-24. PubMed ID: 7012408
    [No Abstract]   [Full Text] [Related]  

  • 31. [A case of arterial thrombosis successfully treated with a large dosage of urokinase--study on urokinase administration with special reference to alpha2-plasmin inhibitor (author's transl)].
    Hayashi S; Yamada K
    Rinsho Ketsueki; 1979 Apr; 20(4):400-9. PubMed ID: 156270
    [No Abstract]   [Full Text] [Related]  

  • 32. Human renal microvascular endothelial cells as a potential target in the development of the hemolytic uremic syndrome as related to fibrinolysis factor expression, in vitro.
    Louise CB; Obrig TG
    Microvasc Res; 1994 May; 47(3):377-87. PubMed ID: 8084301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic lupus erythematosus in a multiethnic US cohort: XXXIV. Deficient mannose-binding lectin exon 1 polymorphisms are associated with cerebrovascular but not with other arterial thrombotic events.
    Calvo-Alén J; Alarcón GS; Tew MB; Tan FK; McGwin G; Fessler BJ; Vilá LM; Reveille JD;
    Arthritis Rheum; 2006 Jun; 54(6):1940-5. PubMed ID: 16729310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Renal vascular lesion and microangiopathic hemolytic anemia in systemic lupus erythematosus].
    Gnocchi CA; Yaryour C; Kohan A; De Rosa G; Nadal M
    Medicina (B Aires); 1997; 57(2):200-4. PubMed ID: 9532830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Thrombotic microangiopathy in a patient with systemic lupus erythematosus].
    Caravaca F; Fernández-Alonso J; Arrobas M; Cubero JJ; Pizarro JL; Sánchez-Casado E
    Med Clin (Barc); 1987 Dec; 89(20):870-2. PubMed ID: 3448441
    [No Abstract]   [Full Text] [Related]  

  • 36. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH; Rijken DC
    Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The frequency of thrombotic thrombocytopenic purpura in patients with systemic lupus erythematosus undergoing kidney biopsy.
    Manadan AM; Harris C; Schwartz MM; Block JA
    J Rheumatol; 2003 Jun; 30(6):1227-30. PubMed ID: 12784394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An assessment of regional versus systemic thrombolytic treatment of peripheral and coronary artery thrombosis.
    Marder VJ; Francis CW
    Prog Hemost Thromb; 1984; 7():325-56. PubMed ID: 6241729
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pharmacologic aspects of thrombophilia].
    Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(4):535-49. PubMed ID: 6083924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abnormalities of fibrinolysis in essential hypertension.
    Ettenger MM; MacCarthy EP; Glas-Greenwalt P; Clyne DH; Pollak VE
    J Hypertens Suppl; 1984 Dec; 2(3):S175-8. PubMed ID: 6242555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.